{"id":12475,"date":"2022-10-08T02:43:00","date_gmt":"2022-10-08T02:43:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3886691_CN86691_0"},"modified":"2022-10-08T02:43:00","modified_gmt":"2022-10-08T02:43:00","slug":"antengene-announces-upcoming-presentations-at-the-2022-society-for-immunotherapy-of-cancer-annual-meeting","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=12475","title":{"rendered":"Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting"},"content":{"rendered":"<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1662479\/ANTENGENE_EN_Logo.jpg?p=medium600\" border=\"0\" alt title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><b><i>Oral presentation<\/i><\/b><i>&nbsp;highlights preclinical data of <b>ATG-031, an in-house discovered anti-CD24 monoclonal antibody<\/b><\/i><\/li>\n<li><i>Three <b>poster<\/b> <b>presentations <\/b>showcase preclinical data of <b>ATG-101, a PD-L1\/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027, a B7H3\/PD-L1 bispecific antibody discovered in-house<\/b><\/i><\/li>\n<li><i>Antengene has<b> global rights <\/b>to these pipeline assets<\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SHANGHAI<\/span> and <span class=\"xn-location\">HONG KONG<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 8, 2022<\/span><\/span> \/PRNewswire\/ &#8212; At the 37<sup>th<\/sup> Society for Immunotherapy of Cancer Annual Meeting (SITC 2022), set to take place on <span class=\"xn-chron\">November 8-12, 2022<\/span>, in <span class=\"xn-location\">Boston, Massachusetts<\/span> (<span class=\"xn-location\">United States<\/span>),&nbsp;via in person\/virtual attendance, <b>Antengene will release data from preclinical studies of<\/b><b>&nbsp;four pipeline assets,<\/b><b>&nbsp;ATG-031, ATG-101, ATG-018, and ATG-027, in one oral presentation and three poster presentations<\/b>. As the world&#8217;s largest and most anticipated gathering in the field of immuno-oncology, the SITC Annual Meeting is designed to promote scientific exchanges and cooperation&nbsp;for improving treatment outcomes for cancer patients.<\/p>\n<p><b>Details of the oral presentation are shown as below:<\/b><\/p>\n<p><b>Title:<\/b>&nbsp;ATG-031, a first-in-class anti-CD24 antibody, showed potent preclinical anti-tumor efficacy by blocking &#8220;don&#8217;t-eat-me&#8221; signal&nbsp;<br \/><b>Abstract#:<\/b>&nbsp;482<br \/><b>Date: <\/b><span class=\"xn-chron\">November 11, 2022<\/span><br \/><b>Time:<\/b>&nbsp;5:20 PM \u2013 <span class=\"xn-chron\">5:35 PM (Eastern Time)<\/span><br \/>(<span class=\"xn-chron\">6:20 AM<\/span> \u2013 <span class=\"xn-chron\">6:35 AM<\/span> Beijing Time, <span class=\"xn-chron\">November 12, 2022<\/span>)<br \/><b>Presenter:<\/b>&nbsp;Dr. <span class=\"xn-person\">Jay Mei<\/span>, Antengene<br \/><b>First Author: <\/b>Dr. <span class=\"xn-person\">Peng Chen<\/span>, Antengene<br \/><b>Corresponding <\/b><b>Authors<\/b><b>:<\/b>&nbsp;Dr. <span class=\"xn-person\">Bo Shan<\/span>, Dr.&nbsp;Bing Hou, Antengene<\/p>\n<p><b>Details of those three poster presentations are shown below<\/b><b>. All posters will be presented at<\/b><b>:<br \/><\/b><span class=\"xn-chron\">9:00 AM<\/span> \u2013 <span class=\"xn-chron\">9:00 PM (Eastern Time)<\/span><br \/>(<span class=\"xn-chron\">10:00 PM<\/span> November <span class=\"xn-chron\">10 to 10:00 AM<\/span> <span class=\"xn-chron\">November 11, 2022<\/span> Beijing Time)<\/p>\n<p><b>Title: <\/b>ATG-101, a tetravalent PD-L1\u00d74-1BB BsAb, demonstrates potent <i>in vivo<\/i> anti-tumor efficacy in ICI-resistant or refectory mouse tumor models<br \/><b>Abstract#:<\/b>&nbsp;1150<br \/><b>Date: <\/b><span class=\"xn-chron\">November 10, 2022<\/span><br \/><b>Presenter:<\/b>&nbsp;Dr. Bing Hou, Antengene<br \/><b>First Author: <\/b>Dr. <span class=\"xn-person\">Wenhui Yu<\/span>, Antengene<br \/><b>Corresponding Authors:<\/b>&nbsp;Dr. <span class=\"xn-person\">Bo Shan<\/span>, Dr. Bing Hou, Antengene<\/p>\n<p><b>Title: <\/b>Discovery of blood pharmacodynamic biomarkers for ATR inhibitors<br \/><b>Abstract#<\/b>: 76<br \/><b>Date: <\/b><span class=\"xn-chron\">November 10, 2022<\/span><br \/><b>Presenter:<\/b>&nbsp;Dr. Bin Jiang, Antengene<br \/><b>First Author: <\/b>Dr. Ya Kong, Antengene<br \/><b>Corresponding <\/b><b>Authors<\/b><b>:<\/b>&nbsp;Dr. <span class=\"xn-person\">Shan Bo<\/span>, Dr. Bing Hou, Antengene<\/p>\n<p><b>Title: <\/b>ATG-027, a first-in-class B7-H3\/PD-L1 bispecific antibody, shows potent T cell activation capability and<i> in vivo <\/i>anti-tumor efficacy<br \/><b>Abstract#:<\/b>&nbsp;1397<br \/><b>Date: <\/b><span class=\"xn-chron\">November 10, 2022<\/span><br \/><b>Presenter:<\/b>&nbsp;Dr. <span class=\"xn-person\">Linjie Tian<\/span>, Antengene<br \/><b>First Author: <\/b>Dr. <span class=\"xn-person\">Wenhui Yu<\/span>, Antengene<br \/><b>Corresponding <\/b><b>Authors<\/b><b>:<\/b>&nbsp;Dr. <span class=\"xn-person\">Bo Shan<\/span>, Dr. Bing Hou, Antengene<\/p>\n<p><b>About Antengene<\/b><\/p>\n<p>Antengene Corporation Limited (<b>&#8220;Antengene&#8221;<\/b>, SEHK: 6996.HK) is a leading commercial-stage R&amp;D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class\/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of <b>&#8220;Treating Patients Beyond Borders&#8221;.<\/b><\/p>\n<p>Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for <span class=\"xn-location\">Asia Pacific<\/span> markets including the <span class=\"xn-location\">Greater China<\/span> region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and <span class=\"xn-location\">Asia<\/span>, and submitted 6 new drug applications (NDAs) in multiple <span class=\"xn-location\">Asia Pacific<\/span> markets, with the NDA for XPOVIO\u00ae (selinexor), already approved in mainland <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">South Korea<\/span>, <span class=\"xn-location\">Singapore<\/span> and <span class=\"xn-location\">Australia<\/span>.<\/p>\n<p><b>Forward-looking statements<\/b><\/p>\n<p>The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled &#8220;Risk Factors&#8221; in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company&#8217;s Annual Report for year-end <span class=\"xn-chron\">December 31, 2021<\/span>, and subsequent filings with the Hong Kong Stock Exchange.<\/p>\n<p>For more information, please contact:<\/p>\n<p>Investor Contacts:&nbsp;<br \/><span class=\"xn-person\">Donald Lung<\/span><br \/>E-mail: <a href=\"mailto:Donald.Lung@antengene.com%C2%A0\" rel=\"nofollow\">Donald.Lung@antengene.com&nbsp;<\/a><br \/>Mobile: +86 18420672158<\/p>\n<p>PR Contacts:<br \/><span class=\"xn-person\">Peter Qian<\/span><br \/>E-mail: <a href=\"mailto:Peter.Qian@antengene.com\" rel=\"nofollow\">Peter.Qian@antengene.com<\/a><br \/>Mobile: +86 13062747000<\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN86691&amp;sd=2022-10-07\"> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/antengene-announces-upcoming-presentations-at-the-2022-society-for-immunotherapy-of-cancer-annual-meeting-301644155.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/antengene-announces-upcoming-presentations-at-the-2022-society-for-immunotherapy-of-cancer-annual-meeting-301644155.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oral presentation&nbsp;highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody Three poster presentations showcase preclinical data of ATG-101, a PD-L1\/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027, a B7H3\/PD-L1 bispecific antibody discovered in-house Antengene has global rights to these pipeline assets SHANGHAI and HONG KONG, Oct. 8, 2022 [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-12475","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=12475\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting - My Blog\" \/>\n<meta property=\"og:description\" content=\"Oral presentation&nbsp;highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody Three poster presentations showcase preclinical data of ATG-101, a PD-L1\/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027, a B7H3\/PD-L1 bispecific antibody discovered in-house Antengene has global rights to these pipeline assets SHANGHAI and HONG KONG, Oct. 8, 2022 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=12475\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-08T02:43:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/1662479\/ANTENGENE_EN_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting\",\"datePublished\":\"2022-10-08T02:43:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475\"},\"wordCount\":746,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1662479\\\/ANTENGENE_EN_Logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475\",\"name\":\"Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1662479\\\/ANTENGENE_EN_Logo.jpg?p=medium600\",\"datePublished\":\"2022-10-08T02:43:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1662479\\\/ANTENGENE_EN_Logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1662479\\\/ANTENGENE_EN_Logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=12475#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=12475","og_locale":"en_US","og_type":"article","og_title":"Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting - My Blog","og_description":"Oral presentation&nbsp;highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody Three poster presentations showcase preclinical data of ATG-101, a PD-L1\/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027, a B7H3\/PD-L1 bispecific antibody discovered in-house Antengene has global rights to these pipeline assets SHANGHAI and HONG KONG, Oct. 8, 2022 [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=12475","og_site_name":"My Blog","article_published_time":"2022-10-08T02:43:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/1662479\/ANTENGENE_EN_Logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=12475#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=12475"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting","datePublished":"2022-10-08T02:43:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=12475"},"wordCount":746,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=12475#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1662479\/ANTENGENE_EN_Logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=12475","url":"https:\/\/transmediavictoria.net.au\/?p=12475","name":"Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=12475#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=12475#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1662479\/ANTENGENE_EN_Logo.jpg?p=medium600","datePublished":"2022-10-08T02:43:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=12475#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=12475"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=12475#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/1662479\/ANTENGENE_EN_Logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/1662479\/ANTENGENE_EN_Logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=12475#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/12475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12475"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/12475\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}